Recital 5, Directive (EU) 2001/83

In forcecited 18×

Such hindrances must accordingly be removed; whereas this entails approximation of the relevant provisions.

The 10 that are cited most themselves, of 18.

  • Judgment of the Court (Second Chamber) of 8 November 2007. Gintec International Import-Export GmbH v Verband Sozialer Wettbewerb eV.Decision

    In that regard, it is necessary to point out that Directive 2001/83 was adopted on the basis of Article 95 EC, which, in paragraph 1, permits, by way of derogation from Article 94 EC and save where otherwise provided in the EC Treaty, the …

    8 Nov 2007 · 62005CJ0374

  • Judgment of the Court (First Chamber) of 20 September 2007. Staat der Nederlanden v Antroposana, Patiëntenvereniging voor Antroposofische GeDecision

    According to the second, fourth and fifth recitals in the preamble thereto, the purpose of Directive 2001/83 is to ‘safeguard public health’ and to eliminate hindrances to ‘trade in medicinal products within the Community’.

    20 Sep 2007 · 62006CJ0084

  • Judgment of the Court (First Chamber) of 15 November 2007. Commission of the European Communities v Federal Republic of Germany.Decision

    The second to the fifth recitals in the preamble to Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ 2001 L 311, p. 67) state: The …

    15 Nov 2007 · 62005CJ0319

  • Judgment of the Court (Second Chamber), 28 June 2012. Fabio Caronna.Decision

    Recitals 2 to 5 and 35 and 36 of the Directive are worded as follows: The essential aim of any rules governing the production, distribution and use of medicinal products must be to safeguard public health. However, this objective must be …

    28 Jun 2012 · 62011CJ0007

  • Judgment of the Court (First Chamber) of 18 June 2009. The Queen, on the application of Generics (UK) Ltd v Licensing Authority.Decision

    Recitals 2, 4, 5 and 10 in the preamble to Directive 2001/83 state: ‘(2) The essential aim of any rules governing the production, distribution and use of medicinal products must be to safeguard public health. … (4) Trade in medicinal …

    18 Jun 2009 · 62007CJ0527

  • Judgment of the Court (Sixth Chamber) of 15 December 2016. LEK Farmacevtska Družba d.d. v Republika Slovenija.Decision

    Recitals 2 to 5 of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ 2001 L 311, p. 67), as amended by Directive 2011/62/EU of the …

    15 Dec 2016 · 62015CJ0700

  • Opinion of Advocate General Bobek delivered on 7 December 2017. Proceedings brought by Astellas Pharma GmbH.Decision

    In sum, the genuine operation of the decentralised procedure, despite it forming part of a regime heralded as an ‘important step towards achievement of the objective of the free movement of medicinal products’, [Recital 14 of the …

    7 Dec 2017 · 62016CC0557

  • Opinion of Mr Advocate General Ruiz-Jarabo Colomer delivered on 13 February 2007. Gintec International Import-Export GmbH v Verband SozialerDecision

    The German Government correctly argues that minimum harmonisation does not always hinder this freedom of movement and does not necessarily entail the fragmentation of the single market. However, if the hindrances to this freedom arise from …

    13 Feb 2007 · 62005CC0374

  • Judgment of the Court (Eighth Chamber) of 23 April 2020. Deutsche Homöopathie-Union (DHU) Arzneimittel GmbH & Co. KG v Bundesrepublik DeutscDecision

    Recitals 2, 5, 17, 21, 23, 25 and 40 of Directive 2001/83 are worded as follows: The essential aim of any rules governing the production, distribution and use of medicinal products must be to safeguard public health. … Such hindrances …

    23 Apr 2020 · 62019CJ0101

  • Opinion of Advocate General Jääskinen delivered on 29 September 2011. European Commission v Republic of Poland.Decision

    More precisely, the aim of the marketing authorisation requirement in Article 6(1) of Directive 2001/83 is to guarantee that the potential risks of products are outweighed by their therapeutic efficacy, which is assessed on the basis of …

    29 Sep 2011 · 62010CC0185